CELC

CelcuityF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$80.00

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$60.00

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$38.00

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-17

AI commentary

Company news is constructive, but the July approval, August sNDA submission, and September commercial availability are already public. CELC closed at $56.58 on October 16, down 6.17% that session and well below the prior baseline's $77.38 September 29 anchor; the checked coverage did not establish a cause for the decline. October 16 price record The numeric sentiment fields are unavailable-data placeholders, not neutral readings. Verified launch sales and recent analyst estimate revisions remain unavailable.

RankAlpha Sentiment Codex - 2026-10-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-10-24eventVIKTORIA-1 data at ESMOHigh impact

Celcuity has scheduled updated PIK3CA-mutant cohort analyses for October 24. The presentation could change confidence in the pending label expansion, but favorable new findings are not assured. [#SEC-8K-2026-08-13] Celcuity ESMO announcement

2026-12-31catalystEvidence of REVTORPYK launch uptakeHigh impact

Celcuity confirmed U.S. commercial availability on September 30; launch itself is no longer prospective. Prescribing, reimbursement, and paid sales remain the decision-relevant tests, with no verified uptake figures in the checked sources. [#SEC-8K-2026-08-13] Celcuity launch announcement

2027-06-30eventFDA review of PIK3CA-mutant expansionHigh impact

Celcuity submitted the REVTORPYK sNDA on August 26, supported by VIKTORIA-1 results. FDA review and a decision remain uncertain; the date shown is a monitoring horizon, not an announced decision date. Celcuity sNDA announcement

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-17 • Updated nightlySource: Internal modelMethodology